pCR and 2-Year Disease-Free Survival: A Combination of the Two Endpoints as a New Classification for Locally Advanced Rectal Cancer Patients-An Updated Pooled Analysis of Eleven International Randomized Trials
- Author(s)
- Gambacorta, MA; Chiloiro, G; Masciocchi, C; Mariani, S; Romano, A; Gonnelli, A; Gerard, JP; Ngan, S; Rodel, C; Bujko, K; Glynne-Jones, R; van Soest, J; Dekker, A; Damiani, A; Valentini, V;
- Details
- Publication Year 2023-06-16,Volume 15,Issue #12,Page 3209
- Journal Title
- Cancers
- Publication Type
- Research article
- Abstract
- LARC is managed by multimodal treatments whose intensity can be highly modulated. In this context, we need surrogate endpoints to help predict long-term outcomes and better personalize treatments. A previous study identified 2yDFS as a stronger predictor of OS than pCR in LARC patients undergoing neoadjuvant RT. The aim of this pooled analysis was to assess the role of pCR and 2yDFS as surrogate endpoints for OS in a larger cohort. The pooled and subgroup analyses were performed on large rectal cancer randomized trial cohorts who received long-course RT. Our analysis focused on the evaluation of OS in relation to the pCR and 2-year disease status. A total of 4600 patients were analyzed. Four groups were identified according to intermediate outcomes: 12% had both pCR and 2yDFS (the better); 67% achieved 2yDFS but not pCR (the good); 1% had pCR but not 2yDFS; and 20% had neither pCR nor 2yDFS (the bad). The pCR and 2yDFS were favorably associated with OS in the univariate analysis, and 2yDFS maintained a statistically significant association in the multivariate analysis independently of the pCR status. The combination of the pCR and 2yDFS results in a strong predictor of OS, whereas failure to achieve 2yDFS carries a poor prognosis regardless of the pCR status. This new stratification of LARC patients could help design predictive models where the combination of 2yDFS and pCR should be employed as the primary outcome.
- Publisher
- MDPI
- Keywords
- disease-free survival; intermediate endpoints; new risk-based classification; pathological complete response; personalized treatment; rectal cancer
- Department(s)
- Radiation Oncology
- PubMed ID
- 37370819
- Publisher's Version
- https://doi.org/10.3390/cancers15123209
- Open Access at Publisher's Site
https://doi.org/10.3390/cancers15123209- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-09-14 03:09:13
Last Modified: 2023-09-14 03:09:44